explore -WSS

explore

author：fashion 2025-09-05 11:31:31 - browse：24

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Hospitals consider fixing cancer drug shortages on their own

WSS

FDA panel endorses Alnylam’s heart drug — after picking it apart

Diverse clinical trials: Why aren’t we there yet?

Walmart eyes Medicare Advantage provider ChenMed

Abortion pill Supreme Court ruling could impact entire drug industry

Steward Health Care has deal to sell doctor network to UnitedHealth

Covid vaccine financial winners and losers, from Pfizer to Novavax

focus

explore

knowledge

Walensky prepares to leave CDC — and Congress — behind

FDA's naming rule on biosimilars has undermined competition

Novavax promises a turnaround & Lilly roils the obesity market

Steward Health Care has deal to sell doctor network to UnitedHealth

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why the world’s most expensive drug might be worth the price

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

PEPFAR is under serious threat — and so is global health

23andMe had bad news about my health. I wish a person had delivered it

Donor acceptance rates hint at racial, gender bias in heart transplants: study

focus

Vertex Pharmaceuticals may move headquarters in Boston

What to make of Biden’s latest efforts on cancer research

Walmart eyes Medicare Advantage provider ChenMed

Long Covid needs a new name — and a new frame

Private equity could exacerbate cardiology's overuse problem, experts fear

Oprah kicked off a national conversation on obesity. Let's have it

Wikipedia

hotspot

focus

entertainment